Astera Labs (ALAB) CEO’s trust sells 157,500 shares but keeps large stake
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Astera Labs, Inc. director and Chief Executive Officer Mohan Jitendra reported that a living trust associated with him sold 157,500 shares of common stock in open-market transactions on March 17, 2026, under a pre-arranged Rule 10b5-1 trading plan adopted on December 1, 2025.
The sales were executed indirectly through the living trust at weighted-average prices generally between about $125 and $135 per share, in multiple tranches. After these transactions, the filing shows the living trust holding 4,531,732 shares, and it also lists additional indirect holdings in several estate planning trusts and 1,452,739 shares held directly, with Jitendra disclaiming beneficial ownership of the trust-held shares except for any pecuniary interest.
Positive
- None.
Negative
- None.
Insights
Pre-planned trust sales by Astera Labs’ CEO, leaving a large remaining stake.
Astera Labs CEO and director Mohan Jitendra reported net open-market sales of 157,500 common shares on March 17, 2026. The transactions were executed by a living trust associated with him, not directly by Jitendra, and are classified as routine open-market sales.
A key detail is that these trades occurred automatically under a Rule 10b5-1 trading plan adopted on December 1, 2025, indicating they were pre-scheduled rather than opportunistic. After the sales, the living trust still holds 4,531,732 shares, and the filing lists additional indirect trust holdings plus 1,452,739 shares held directly.
This combination of a large remaining position and pre-planned status generally frames the activity as portfolio diversification or liquidity management rather than a strong directional signal on the company’s prospects. Subsequent company filings may provide further context on Jitendra’s overall ownership and any future trading plan activity.
Insider Trade Summary 10b5-1
Net Seller: 157,500 shares ($20,723,773)
Net Sell
16 txns
Insider
Mohan Jitendra
Role
Chief Executive Officer
Sold
157,500 shs ($20.72M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 8,754 | $125.5575 | $1.10M |
| Sale | Common Stock | 5,746 | $126.6444 | $728K |
| Sale | Common Stock | 3,624 | $127.4731 | $462K |
| Sale | Common Stock | 7,907 | $128.6415 | $1.02M |
| Sale | Common Stock | 11,120 | $129.6162 | $1.44M |
| Sale | Common Stock | 13,880 | $130.741 | $1.81M |
| Sale | Common Stock | 22,766 | $131.6101 | $3.00M |
| Sale | Common Stock | 43,289 | $132.7214 | $5.75M |
| Sale | Common Stock | 22,309 | $133.6642 | $2.98M |
| Sale | Common Stock | 18,105 | $134.6738 | $2.44M |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 4,680,478 shares (Indirect, By Living Trust);
Common Stock — 1,452,739 shares (Direct)
Footnotes (1)
- The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2025. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $125.0700 to $126.0000, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. These shares are owned directly by a living trust (the "Living Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $126.0800 to $127.0600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $127.1100 to $128.0400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $128.1500 to $129.1300, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $129.1600 to $130.1500, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $130.1600 to $131.1500, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $131.1600 to $132.1400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $132.1750 to $133.1700, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $133.1775 to $134.1400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $134.2000 to $135.1400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. These shares are owned directly by an estate planning trust (the "Trust"). The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. These shares are owned directly by an estate planning trust (the "2021 Trust 1"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. These shares are owned directly by an estate planning trust (the "2021 Trust 2"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. These shares are owned directly by an estate planning trust (the "2022 Trust 1"). The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. These shares are owned directly by an estate planning trust (the "2022 Trust 2"). The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
FAQ
What insider transaction did Astera Labs (ALAB) disclose for its CEO?
Astera Labs disclosed that a living trust associated with CEO Mohan Jitendra sold 157,500 common shares. The sales occurred on March 17, 2026, as open-market transactions and were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 1, 2025.
Were the Astera Labs (ALAB) insider sales part of a Rule 10b5-1 plan?
Yes, the filing states the sales occurred automatically under a Rule 10b5-1 trading plan. That plan was adopted by the reporting person on December 1, 2025, meaning the March 17, 2026 transactions were pre-scheduled rather than discretionary market-timing trades.